Pharmaceutical Market Europe • April 2021 • 3
COMMENT
After a year of virtual congresses, Chris Ross looks at what we’ve learned in the last 12 months and what pharma can do to improve the virtual experience by continuing to design congresses around known customer behaviours and needs.
In his article on page 26, Chris says: “A recent study of healthcare professionals’ experiences of virtual congresses revealed that, despite the convenience of remote models, HCPs are actually more time restricted in a virtual world.
“Where physical congresses give doctors ‘protected time’ to interact and learn, their virtual equivalents typically compete with routine daily duties, professional and personal. As a result, HCPs spend less time engaging with educational content than they would do if they attended in person.”
Although a virtual experience may never completely replicate all the benefits of being face to face, it is likely that a hybrid experience will be the new normal, offering compelling, engaging and enduring content that reinforces learning and provides long-term value beyond the event.
Continuing on from our coverage last month marking Rare Disease Day, in this issue we highlight the struggles experienced by patients with rare diseases seeking access to gene and cell therapies.
Our article on page 20 looks at EU cross-border healthcare and emphasises that the clock is ticking to improve patient access to rare disease therapies. The very survival of these patients depends on these therapies, yet they face a flurry of challenges to access the treatments that will hopefully change their lives forever.
With the disease expertise and specialist skills that are required not being widely available in every European country, a functioning cross-border healthcare framework at the EU level is essential. Read more on page 20.
I hope you enjoy this issue!
Iona Everson
Group Managing Editor
Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at www.pmlive.com/register
THE TEAM
Editorial:
Group Managing Editor
Iona Everson
Reporter
Lucy Parsons
Studio:
Executive Director
Karl Equi
Middleweight Graphic Designer
Helen Penfold
Sales:
Business Director
Tara Lovegrove
EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation
Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim
Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences
Stefan Janssens
President EMEA, Cegedim Dendrite
John Morris
Partner, KPMG
Paul Pay
Chief business development officer, Norgine
Mark Rothera
Chief executive officer, Orchard Therapeutics
Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals
PUBLISHED BY
PMGroup
Mansard House, Church Road, Little Bookham, Surrey, KT23 3JG, UK
Tel: +44 (0)1372 414200
Fax: +44 (0)1372 414201
CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com
Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.
© 2021 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.
The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW